{"analyses":[{"ciLowerLimit":"0.165","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.475","estimateComment":"Stratified by RET mutation type (M918T vs. Others) and intended treatment if randomized to Arm B (Vandetanib vs. Cabozantinib).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.280","statisticalComment":"Stratified by RET mutation type (M918T vs. Others) and intended treatment if randomized to Arm B (Vandetanib vs. Cabozantinib).","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Data unavailable due to high censoring.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"12.22","upperLimit":"25.10","value":"16.76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization until the occurrence of documented disease progression by the BICR, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria, or death from any cause in the absence of BICR-documented progressive disease.\n\nProgressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"160 milligrams Selpercatinib administered orally (PO) twice daily (BID).\n\nAdolescent Dose: 92 mg/m2 BID (not to exceed 160 mg BID).","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"140 mg Cabozantinib administered orally daily (QD) or 300 mg Vandetanib administered orally QD per physician choice.\n\nCabozantinib Adolescent Dose: 40 mg/m2.\n\nVandetanib Adolescent Dose:\n\n* 0.7 - \\<0.9 - 100 mg every other day (QOD)\n* 0.9 - \\<1.2 - 100 mg QD\n* 1.2 - \\<1.6 - 7-day schedule 100 mg - 200 mg - 100 mg - 200 mg - 100 mg - 200 mg - 100 mg\n* ≥1.6 - 200 QD","id":"OG001","title":"Cabozantinib or Vandetanib (TRT B)"}],"paramType":"MEDIAN","populationDescription":"All randomized participants, even if a participant did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol. Censored participants: Selpercatinib - 167; Cabozantinib or Vandetanib - 66","reportingStatus":"POSTED","timeFrame":"Baseline to Progressive Disease or Death from Any Cause, Whichever Occurs First, Up to 39 Months","title":"Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)","type":"PRIMARY","unitOfMeasure":"Months"}